Joshua M. Bauml, MD

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses the significant impacts of a new electronic platform.

Bauml hopes the new platform will enhance clinical trial enrollment in lung cancer. To achieve this, first the feasibility of the approach had to be established. Bauml and his team considered whether the platform was burdensome or overwhelming to patients as well. However, he found that patients tend to like this type of technology.

The rate of clinical trial enrollment is 5% nationally and 10%-15% in an academic center, says Bauml. He adds that he and his team were able to achieve 40% clinical trial enrollment, which included those who were appropriate for therapy change.

Videos

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses the significant impacts of a new electronic platform.


Joshua M. Bauml, MD | Authors

Articles

Dr. Bauml Discusses a New Electronic Platform for Clinical Trial Enrollment in Lung Cancer